| Cilloni, Daniela |
| Recruiting | 3 | 172 | Europe | Cytarabine, Daunorubicin, Midostaurin, Cytarabine HD | Gruppo Italiano Malattie EMatologiche dell'Adulto, MYNERVA (MYeloid Neoplasms Research Venture AIRC) programma speciale finanziato dall'AIRC - Associazione Italiana per la, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | Acute Myeloid Leukemia With FLT3/ITD Mutation | 12/22 | 08/25 | | |
| Recruiting | 3 | 414 | Europe | Gemtuzumab Ozogamicin | Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L. | Acute Myeloid Leukemia | 04/25 | 04/27 | | |
| Recruiting | 3 | 274 | Europe | Azacitidine, AZA, Standard Chemotherapy, STD CHT, Allogeneic stem cell transplantation, HSCT | Gruppo Italiano Malattie EMatologiche dell'Adulto, AIFA - Italian Medicines Agency, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus | High-risk MDS | 03/24 | 03/24 | | |
| Not yet recruiting | 3 | 339 | Europe, RoW | High intensity therapies, Low intensity therapies | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX | Acute Myeloid Leukemia, Relapse/Recurrence | 01/28 | 01/28 | | |
| Active, not recruiting | 2 | 21 | Europe, US, RoW | GB2064 | Galecto Biotech AB, OPIS s.r.l | Myelofibrosis | 12/23 | 06/26 | | |
| Recruiting | 2 | 32 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA | Chemotherapy, Leukemia, Acute Lymphoblastic | 02/25 | 07/28 | | |
| Active, not recruiting | 2 | 68 | Europe | AG-120 | Groupe Francophone des Myelodysplasies | Myelodysplastic Syndromes, Acute Myeloid Leukemia | 04/25 | 04/25 | | |
SENTRY-2, NCT05980806: A Study of Selinexor Monotherapy in Subjects with JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia |
|
|
| Recruiting | 2 | 118 | Europe, Canada, US, RoW | Selinexor 60 mg, KPT-330, Selinexor 40 mg, Ruxolitinib, JAKAFI, Pacritinib, VONJO, Momelotinib, OJJAARA | Karyopharm Therapeutics Inc | Myelofibrosis, Moderate Thrombocytopenia | 04/26 | 10/28 | | |
| Recruiting | N/A | 343 | Europe, RoW | Questionnaire | Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC | Acute Myeloid Leukemia | 06/21 | 12/22 | | |
NCT03789981: Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia |
|
|
| Active, not recruiting | N/A | 75 | Europe | Immunogenic profile | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Acute Myeloid Leukemia | 12/24 | 12/25 | | |
RUX-MF, NCT06516406: Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera |
|
|
| Recruiting | N/A | 1055 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Myelofibrosis, Primary Myelofibrosis, Secondary Myelofibrosis | 05/32 | 05/32 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96 |
|
|
| Recruiting | N/A | 104 | Europe | Venetoclax plus HMA | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 12/22 | 12/23 | | |
| Completed | N/A | 215 | Europe | Luspatercept | Fondazione Italiana Sindromi Mielodisplastiche-ETS, Istituto Clinico Humanitas | Myeloid Dysplasia | 12/22 | 01/23 | | |
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms |
|
|
| Recruiting | N/A | 237 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes | 03/25 | 03/25 | | |
| Not yet recruiting | N/A | 100 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | VEXAS | 02/25 | 06/25 | | |
NCT05553873: Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study. |
|
|
| Recruiting | N/A | 500 | Europe | | University of Milano Bicocca | Myeloproliferative Disease, Inflammatory Markers | 12/26 | 12/26 | | |
